

H. Lundbeck A/S

Ottiliavej 9
DK-2500 Valby, Copenhagen
CVR number: 56759913

Tel +45 36 30 13 11
Fax +45 36 43 82 62

E-mail investor@lundbeck.com
www.lundbeck.com



Corporate Release No 418

23 November 2010

Financial calendar 2011

H. Lundbeck A/S has planned the following dates in 2011 for the financial statements, the Annual General Meeting and payment of annual dividend.

24 February 2011	Annual report 2010
30 March 2011	Annual General Meeting
5 April 2011	Payment of annual dividend
4 May 2011	Interim report for the first quarter of 2011
10 August 2011	Interim report for the second quarter of 2011
9 November 2011	Interim report for the third quarter of 2011

Lundbeck contacts

Investors:

Palle Holm Olesen
Chief Specialist, Investor Relations
+45 36 43 24 26

Magnus Thorstholm Jensen
Investor Relations Officer
+45 36 43 38 16

Jacob Tolstrup
Vice President
+1 847 282 5713

Media:

Mads Kronborg
Media Relations Manager
+45 36 43 28 51

Stine Hove Marsling
External Communication Specialist
+45 36 43 28 33

About Lundbeck

H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical company highly committed to improving the quality of life for people suffering from central nervous system (CNS) disorders. For this purpose, Lundbeck is engaged in the research and development, production, marketing and sale of pharmaceuticals across the world. The company's products are targeted at disorders such as depression and anxiety, schizophrenia, insomnia, epilepsy and Huntington's, Alzheimer's and Parkinson's diseases.

Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark. Today Lundbeck employs approximately 5,900 people worldwide. Lundbeck is one of the world's leading pharmaceutical companies working with CNS disorders. In 2009, the company's revenue was DKK 13.7 billion (approximately EUR 1.8 billion or USD 2.6 billion). For more information, please visit www.lundbeck.com.